• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppression.雷珠单抗玻璃体内植入给药系统（RPDS）：实现了长期以来对延长血管内皮生长因子抑制作用的梦想。
Eye (Lond). 2020 Mar;34(3):422-423. doi: 10.1038/s41433-019-0479-y. Epub 2019 Jun 5.
2
CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.玻璃体腔内注射贝伐单抗、阿柏西普或雷珠单抗治疗糖尿病性黄斑水肿后血浆血管内皮生长因子水平的变化。
Retina. 2018 Sep;38(9):1801-1808. doi: 10.1097/IAE.0000000000002004.
3
Fluctuation Speed as a New Criterion to Evaluate the Efficiency of Intravitreal Anti-VEGF Drugs.波动速度作为评估玻璃体内抗VEGF药物疗效的新指标
Ophthalmologica. 2016;235(4):242. doi: 10.1159/000445877. Epub 2016 Apr 21.
4
Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.玻璃体内注射阿柏西普、贝伐单抗和雷珠单抗后新生兔视网膜的组织学和免疫组织化学变化
Curr Eye Res. 2017 Feb;42(2):315-322. doi: 10.3109/02713683.2016.1164190. Epub 2016 Jun 17.
5
REPORT OF SAFETY OF THE USE OF A SHORT 32G NEEDLE FOR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR RETINOPATHY OF PREMATURITY: A Multicenter Study.用于早产儿视网膜病变玻璃体腔内抗血管内皮生长因子注射的32G短针使用安全性报告：一项多中心研究
Retina. 2018 Jun;38(6):1251-1255. doi: 10.1097/IAE.0000000000002172.
6
Intravitreal Anti-VEGF Pharmacotherapy and Kidney Failure: Protecting Vision with an Eye on Renal Safety.玻璃体内抗血管内皮生长因子药物治疗与肾衰竭：关注肾脏安全性以保护视力
Ophthalmol Retina. 2024 Aug;8(8):731-732. doi: 10.1016/j.oret.2024.04.018.
7
SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.玻璃体内注射阿柏西普、贝伐单抗和雷珠单抗的全身药代动力学和药效学
Retina. 2017 Oct;37(10):1847-1858. doi: 10.1097/IAE.0000000000001493.
8
Short term effects of intravitreal anti-vascular endothelial growth factor agents on cornea, anterior chamber, and intraocular pressure.玻璃体内抗血管内皮生长因子药物对角膜、前房和眼压的短期影响。
Cutan Ocul Toxicol. 2019 Dec;38(4):344-348. doi: 10.1080/15569527.2019.1616749. Epub 2019 May 30.
9
Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.玻璃体内抗血管内皮生长因子治疗作为治疗中心性近视脉络膜新生血管的一线治疗药物：贝伐单抗或雷珠单抗的长期疗效。
Eye (Lond). 2012 Jul;26(7):1004-11. doi: 10.1038/eye.2012.97. Epub 2012 May 18.
10
Acute renal failure after intravitreal antivascular endothelial growth factor therapy.玻璃体内抗血管内皮生长因子治疗后急性肾衰竭
J Formos Med Assoc. 2017 Jun;116(6):490-492. doi: 10.1016/j.jfma.2016.09.010. Epub 2016 Nov 2.

引用本文的文献

1
Save our Sight (SOS): a collective call-to-action for enhanced retinal care across health systems in high income countries.拯救我们的视力（SOS）：高收入国家呼吁在整个卫生系统中加强视网膜护理
Eye (Lond). 2023 Nov;37(16):3351-3359. doi: 10.1038/s41433-023-02540-w. Epub 2023 Jun 6.
2
Port delivery system with ranibizumab (Susvimo) recall- What does it mean to the retina specialists.雷珠单抗（Susvimo）眼内注射递送系统召回——这对视网膜专家意味着什么。
Int J Retina Vitreous. 2023 Jan 30;9(1):6. doi: 10.1186/s40942-023-00446-z.
3
International consortium for innovation and quality: An industry perspective on the nonclinical and early clinical development of intravitreal drugs.国际创新与质量联盟：眼内药物非临床和早期临床开发的行业视角。
Clin Transl Sci. 2023 May;16(5):723-741. doi: 10.1111/cts.13480. Epub 2023 Feb 2.
4
Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis.抗血管内皮生长因子药物及其用于抑制视网膜新生血管的持续释放策略的进展与挑战。
Drug Des Devel Ther. 2022 Sep 22;16:3241-3262. doi: 10.2147/DDDT.S383101. eCollection 2022.
5
Ranibizumab port delivery system in neovascular age-related macular degeneration.雷珠单抗玻璃体内注射植入系统治疗新生血管性年龄相关性黄斑变性
Ther Adv Ophthalmol. 2022 Feb 7;14:25158414211072623. doi: 10.1177/25158414211072623. eCollection 2022 Jan-Dec.

Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppression.

作者信息

Sharma Ashish, Kumar Nilesh, Parachuri Nikulaa, Kuppermann Baruch D, Bandello Francesco, Regillo Carl D

机构信息

Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, TamilNadu, 641014, India.

Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, 92697, USA.

出版信息

Eye (Lond). 2020 Mar;34(3):422-423. doi: 10.1038/s41433-019-0479-y. Epub 2019 Jun 5.

DOI:10.1038/s41433-019-0479-y
PMID:31165769
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7055590/
Abstract
摘要